BA3071 + Nivolumab for Cancer
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research shows that Nivolumab, a part of this drug combination, has been effective in improving survival in patients with advanced melanoma and has shown activity in treating advanced lung cancer. This suggests potential benefits when used in combination with other treatments like BA3071.
12345Nivolumab, used in cancer treatment, can cause immune-related side effects, including issues with the thyroid and other endocrine (hormone-related) problems. These side effects may limit the safety and continuation of therapy.
56789BA3071 + Nivolumab is unique because it combines a novel treatment, BA3071 (Evalstotug), with Nivolumab, an established immune checkpoint inhibitor that blocks PD-1 to enhance the body's immune response against cancer. This combination may offer a new approach by potentially improving the effectiveness of Nivolumab, which has already shown benefits in various cancers.
1571011Eligibility Criteria
This trial is for adults (18+) with various advanced solid tumors who haven't been treated with CLTA-4 blocking antibodies. They must be in good physical condition, have normal blood, liver, and kidney functions, and measurable disease. Pregnant or breastfeeding women, those with recent major surgery, significant heart issues, uncontrolled brain metastases or severe allergies to monoclonal antibodies can't participate.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BA3071 in combination with PD-1 inhibitor and chemotherapy to evaluate safety, tolerability, PK, immunogenicity, and antitumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term